What a Calprotectin Test High Means Beyond Inflammatory Bowel Disease

A calprotectin test high means that neutrophils have migrated into the gastrointestinal lining and released their intracellular proteins into the stool, but that abnormal result alone is not a definitive diagnosis of Crohn's disease or ulcerative colitis. At Longevity Benchmark, we evaluate advanced diagnostics to help readers interpret biomarker data with clinical context rather than panic. For a foundational explanation of how clinicians evaluate intestinal disorders, see our guide on how doctors test gut health.

Non-IBD Medication Causes of Elevated Calprotectin

Non-steroidal anti-inflammatory drugs and acid-suppressing proton pump inhibitors are the two most frequent non-IBD medication drivers of a raised fecal calprotectin test.

In a landmark investigation by Tibble and colleagues (1999) involving 312 NSAID users and 48 controls, the prevalence of NSAID enteropathy reached 44 percent. Furthermore, 20 percent of those taking NSAIDs demonstrated intestinal inflammation levels comparable to patients with active inflammatory bowel disease, with prevalence and severity proving independent of drug type or dosage.

In a trial published by Maiden and colleagues (2005), 40 healthy volunteers took slow-release diclofenac (75 milligrams twice daily) along with omeprazole (20 milligrams twice daily) for 14 days. Following this regimen, 75 percent of participants had fecal calprotectin levels exceeding the upper limit of normal, and capsule endoscopy revealed new small-bowel mucosal breaks, red spots, or denuded mucosa in 68 percent of subjects. Because omeprazole was co-administered, some proportion of that increase reflects the proton pump inhibitor rather than the pain reliever alone.

A study by Rendek and co-authors (2016) tested 30 healthy volunteers given 50 milligrams of diclofenac three times daily for two weeks. During treatment, 27 percent exceeded the upper reference limit with a median level of 76 micrograms per gram (range 60 to 958 micrograms per gram). Calprotectin normalized in all participants within two weeks of discontinuing the drug. Earlier crossover trials by Meling and colleagues (1996) demonstrated that 14 days of indomethacin and naproxen increased calprotectin significantly from a baseline of 4.7 milligrams per liter of extract to 9.0 and 8.0 milligrams per liter, respectively.

In 590 individuals with completely normal colonoscopies, Lundgren and colleagues (2019) reported an adjusted odds ratio of 2.411 (95 percent confidence interval 1.162 to 5.002) for NSAID users and 2.934 for aspirin users to show calprotectin above 50 micrograms per gram. Proton pump inhibitors had an even stronger effect, showing an adjusted odds ratio of 3.843 (95 percent confidence interval 2.338 to 6.316). 36 percent of participants with an entirely normal colonoscopy had a calprotectin above 50 micrograms per gram. A 2025 study by Sandberg-Janzon and Karling in 431 patients with functional bowel disorders found recent PPI users had median calprotectin levels of 66 versus 23 micrograms per gram in non-users, with higher levels directly correlated to more recent prescriptions. One smaller study by Moreno Martínez and co-authors (2019) in 33 spondyloarthritis patients did not observe a drop after one month off NSAIDs, indicating underlying inflammatory joint conditions may maintain mucosal permeability.

Clinical Conditions Associated With High Calprotectin

Bacterial gastrointestinal infections, advanced age, colonic neoplasia, diverticular inflammation, and untreated coeliac disease can all elevate fecal calprotectin independently of inflammatory bowel disease.

Age itself shifts baseline neutrophil shedding. In a study of 132 healthy volunteers, Joshi and colleagues (2010) identified median concentrations of 34 micrograms per gram for ages 2 to 9, 22 micrograms per gram for ages 10 to 59, and 27 micrograms per gram for adults aged 60 and older. The upper reference limits were calculated at less than 51 micrograms per gram for individuals aged 10 to 59, but rose to less than 112 micrograms per gram for adults aged 60 and older. Lundgren and colleagues calculated an adjusted odds ratio of 1.051 per year of age for exceeding 50 micrograms per gram. In infants, baseline levels are naturally higher: Campeotto and colleagues (2004) found a median level of 167 micrograms per gram in four-day-old newborns, while Kiss and colleagues (2025) documented medians of 181 micrograms per gram in infants up to 4 months old, dropping to 40.6 micrograms per gram between 4 and 12 months, and 24.7 micrograms per gram between 12 and 36 months. In children aged 4 to 17, Fagerberg and co-authors (2003) found a median of 13.6 micrograms per gram, with 89 percent scoring below 50 micrograms per gram.

Infectious pathogens trigger neutrophil recruitment. Sýkora and co-authors (2010) demonstrated that acute bacterial gastroenteritis produced a median calprotectin of 219 micrograms per gram, compared with 49.3 micrograms per gram in viral gastroenteritis and 26.5 micrograms per gram in healthy controls. In a 2024 pediatric cohort by Vernon-Roberts and colleagues, 89 percent of children presenting with extreme elevations of 500 micrograms per gram or higher had either infectious diarrhea or an eventual diagnosis of inflammatory bowel disease.

Colorectal tumors and polyps also shed inflammatory exudate. In a screening study of 814 high-risk individuals by Kronborg and colleagues (2000), colorectal cancer patients had a median calprotectin of 17.6 milligrams per liter of extract and adenoma patients had 9.1 milligrams per liter, compared to 6.6 milligrams per liter in healthy controls. However, a systematic meta-analysis by von Roon and co-authors (2007) across 5,983 patients established a sensitivity of only 0.36 and specificity of 0.71 for colorectal cancer, concluding the assay cannot serve as a reliable cancer screen. For suspected cancer pathways, Turvill and colleagues (2016) demonstrated a high negative predictive value of 98.6 percent for colorectal cancer, but the positive predictive value for any organic enteric disease was only 32.7 percent. This aligns with NICE recommendation 1.1, which restricts calprotectin testing to adults when colorectal cancer is not suspected.

Diverticular disease presents another source of neutrophil activation. A review by Mohammed and colleagues (2026) found calprotectin averaged 556 to 695 micrograms per gram during acute diverticulitis and reached a median of 181 micrograms per gram in symptomatic uncomplicated diverticular disease, compared to a mean of 50 micrograms per gram in irritable bowel syndrome. Coeliac disease can raise levels in children, though Pathirana and colleagues (2018) noted this is inconsistent in adults, and Segura and co-authors (2025) showed levels fluctuate without correlating with histological healing. The ARUP Laboratories clinical fact sheet highlights that gastrointestinal bleeding causes mild increases in calprotectin concentrations, which is why the BJGP 2024 review and the NHS England consensus pathway both note that guidance advises against calprotectin testing in patients with bloody diarrhoea, who need endoscopic assessment regardless of the result.

Diagnostic Accuracy and Primary Care Specificity Collapse

Diagnostic accuracy for fecal calprotectin is high in secondary hospital clinics but drops markedly when used in unselected primary care populations.

In specialist hospital settings where the prior probability of inflammatory bowel disease is elevated, calprotectin demonstrates excellent diagnostic power. The seminal meta-analysis by van Rheenen and co-authors (2010) across 13 studies found a pooled sensitivity of 0.93 and pooled specificity of 0.96 in adults, alongside a sensitivity of 0.92 and specificity of 0.76 in children. Applying the test avoided 67 percent of adult endoscopies. Similarly, NICE HTG320 section 6.4 cited five studies at a 50 microgram per gram threshold that yielded 93 percent sensitivity and 94 percent specificity. Petryszyn and colleagues (2019) reported a pooled sensitivity of 0.882 and specificity of 0.799 across 19 studies, while a review by Menees and co-authors (2015) concluded that calprotectin at or below 40 micrograms per gram carried a 1 percent or lower probability of inflammatory bowel disease.

When general practitioners use the assay for patients with non-specific abdominal discomfort, performance changes dramatically because actual IBD prevalence is low. In an extensive UK primary care analysis of 5,970 patients by Freeman and colleagues (2021), a 50 microgram per gram cut-off maintained 92.9 percent sensitivity but specificity collapsed to 61.5 percent. The positive predictive value was only 8.1 percent, meaning over 91 percent of patients with a positive test did not have inflammatory bowel disease. Raising the diagnostic threshold to 100 micrograms per gram missed less than 7 percent of additional IBD cases.

Research by Conroy and colleagues (2018) evaluated 410 unselected primary care patients and identified an IBD prevalence of just 2.7 percent. At 50 micrograms per gram, specificity was 64.9 percent and positive predictive value was 5.41 percent. Walker and co-authors (2018) showed that at a 100 microgram per gram threshold, the positive predictive value was 50 percent in patients presenting with red-flag alarm symptoms but dropped to 27 percent in patients without alarm symptoms. Earlier research by Pavlidis and colleagues (2013) in 962 primary care patients found a 28 percent positive predictive value at 50 micrograms per gram, but showed that raising the cut-off to 150 micrograms per gram boosted the positive predictive value to 71 percent while reducing the negative predictive value by only 1 percent. A systematic review by Freeman and colleagues (2019) concluded that conclusive estimates of primary care diagnostic accuracy remain elusive due to method variation.

Clinical False Negatives and Diagnostic Blind Spots

A normal fecal calprotectin result does not entirely exclude organic bowel pathology and is particularly insensitive for microscopic colitis.

While a low calprotectin reliably excludes classic ulcerative colitis or extensive Crohn's disease, it frequently misses microscopic colitis. In an analysis by Münch and co-authors (2020), fecal calprotectin remained below 100 micrograms per gram in over half of patients with active microscopic colitis. This diagnostic limitation creates a systemic vulnerability where patients with collagenous or lymphocytic colitis are incorrectly labeled as having irritable bowel syndrome.

Even in general IBD triage, false negatives occur. In the meta-analysis by van Rheenen and colleagues (2010), diagnostic workup was delayed due to a false negative in 6 percent of adult patients and 8 percent of pediatric patients.

For this reason, the ARUP Laboratories clinical advisory emphasizes that individuals presenting with a high pretest clinical probability of IBD (exceeding 75 percent) should undergo direct endoscopic evaluation regardless of a normal stool test. For other systemic inflammation metrics, compare this with our guide on blood markers such as hsCRP.

Assay Disagreement and Between-Lab Variability

Two independent diagnostic laboratories analyzing identical stool specimens frequently report substantially different calprotectin values because there is no international reference standard.

As highlighted by reviews from Pathirana and colleagues (2018), Reenaers and colleagues (2018), and D'Amico and colleagues (2021), fecal calprotectin testing lacks a universal reference standard, reference measurement procedure, and standardized extraction method. While tests manufactured by different companies generally correlate in direction, quantitative agreement between them is poor. Pathirana documented that optimal receiver operating characteristic cut-points across commercial kits range from 41.3 to 477 micrograms per gram. Furthermore, NICE HTG320 section 6.2 noted a lack of comparative performance data between platforms, encouraging participation in external quality assurance programs like the United Kingdom National External Quality Assessment Service (UK NEQAS).

In a multi-center study by Whitehead and colleagues (2013) evaluating 15 laboratories, the Bühlmann fCAL Turbo reported up to 3.8 times higher calprotectin concentrations on identical samples than assays from Immunodiagnostik and Eurospital. Commercial stool extraction devices also led to a 7.8 to 28.1 percent under-recovery compared to manual weighing methods. In an evaluation of six immunoassays by Oyaert and colleagues (2017), numerical values differed substantially despite similar area-under-the-curve metrics. A two-year longitudinal study by Amcoff and co-authors (2017) demonstrated that at a standard 50 microgram per gram cut-off, the clinical specificity for distinguishing active disease from remission ranged from 34 percent to 75 percent depending on whether a Bühlmann, Phadia, or Immundiagnostik assay was used.

Inter-method comparisons by Handley and colleagues (2023) confirmed that while the Bühlmann fCAL turbo showed good commutability with the Quantum Blue assay (3 percent bias), it displayed a significant 53 percent bias when compared against the DiaSorin Liaison platform. Juricic and colleagues (2019) observed that Bühlmann fCAL Turbo values exceeded EliA Calprotectin results by a mean bias of 32.3 percent using manual weighing and 53.9 percent using extraction devices.

Studies by O'Driscoll and co-authors (2022) and O'Driscoll and co-authors (2025) compared the OC-FCa sensor to the Bühlmann fCAL turbo. They found positive biases between 67.3 percent and 88.4 percent. While agreement was substantial for clearly normal results below 50 micrograms per gram (kappa 0.794) and clearly elevated results above 150 micrograms per gram (kappa 0.788), agreement between platforms collapsed to a kappa of 0.22 to 0.25 in the intermediate 50 to 150 microgram per gram band.

Biological and Day-to-Day Specimen Variability

Biological fluctuations within a single stool and across consecutive days produce meaningful variation in calprotectin readings, especially in active inflammation.

In a study of 18 patients with active ulcerative colitis, Lasson and colleagues (2015) collected 287 stool specimens and observed a median individual coefficient of variation of 52 percent (range 4 to 178 percent) within the very same day. Calprotectin correlated positively with the interval between bowel movements (r = 0.5), suggesting that longer colonic transit times allow greater neutrophil protein accumulation. Calafat and co-authors (2015) similarly reported a median within-day coefficient of variation of 40 percent in active colitis, with the morning bowel movement producing the highest reading in 33.3 percent of patients and the lowest in 38.9 percent.

The degree of day-to-day fluctuation varies depending on disease severity. In 120 patients with inflammatory bowel disease, Cremer and colleagues (2019) demonstrated that variability across punches from a single stool was low (intraclass correlation 0.91, median coefficient of variation 17 percent), but variability across consecutive days was significantly higher (median coefficient of variation 36 percent). Conversely, in quiescent Crohn's disease, Naismith and co-authors (2013) observed high stability across three consecutive days (intraclass correlation 0.84), showing that stable, healed tissue produces consistent readings.

In a 2026 screening trial of 331 asymptomatic first-degree relatives of Crohn's patients by Turner and colleagues, 22 percent of those with an initial elevated calprotectin reading normalized completely on repeat testing. Single measurements must therefore be interpreted cautiously.

Management Pathways for Borderline Calprotectin Test Results

Established clinical guidelines manage borderline calprotectin results between 50 and 250 micrograms per gram by repeating the stool test within four to six weeks before ordering invasive colonoscopies.

The official national guidance contains gaps. While the NICE HTG320 recommendations support calprotectin testing to distinguish irritable bowel syndrome from inflammatory bowel disease, the text contains no numeric diagnostic cut-offs and no repeat-testing protocol. In section 6.5 of the guidance, NICE explicitly notes that its economic modeling assumed all indeterminate results would proceed directly to colonoscopy. Similarly, the American College of Gastroenterology (ACG) 2021 IBS guideline recommends checking calprotectin to rule out inflammatory bowel disease in chronic diarrhea, but offers no guidance on managing intermediate values.

To resolve this ambiguity, the CSO Faecal Calprotectin Working Group pathway endorsed by NHS England established specific intermediate thresholds for adults aged 18 to 60. Results under 100 micrograms per gram indicate inflammatory bowel disease is unlikely and recommend treating for irritable bowel syndrome with a six-week clinical review. Results falling into the intermediate band of 100 to 250 micrograms per gram require a repeat stool test within four weeks. If the repeat test exceeds 250 micrograms per gram, patients are referred urgently to gastroenterology; if it remains between 100 and 250, a routine referral is initiated; if it falls below 100, IBD is considered unlikely. For initial readings above 250 micrograms per gram, clinicians perform a primary care clinical review and refer urgently if symptoms are severe.

The risk of an intermediate result developing into confirmed inflammatory bowel disease remains modest. In an analysis of 443 primary and secondary care patients by McFarlane and colleagues (2016), 19 percent (8 of 41) of patients in the intermediate 50 to 250 microgram per gram band received a new IBD diagnosis within 12 months, compared to 1 percent with normal results and 38 percent with elevated results above 250 micrograms per gram. Irritable bowel syndrome was diagnosed in 27 percent, and 34 percent remained undiagnosed. The odds ratio for an IBD diagnosis with an intermediate result was 26.6 compared to a normal result. The BSG 2018 chronic diarrhoea guideline quotes an 8 percent risk of developing IBD from indeterminate levels (50 to 249 micrograms per gram) based on the broader denominator, compared to 1 percent with levels below 50 micrograms per gram.

Research on the York Faecal Calprotectin Care Pathway by Turvill and colleagues (2018) evaluated an initial cut-off of 100 micrograms per gram followed by repeat testing, achieving 94 percent sensitivity, 92 percent specificity, a 99 percent negative predictive value, and a 51 percent positive predictive value. In a subsequent audit, Turvill (2020) demonstrated that this protocol reduced colonoscopy referral rates from 24 percent to 13 percent. However, as noted in a review by Perry and colleagues in the British Journal of General Practice (BJGP 2024), re-testing protocols introduce potential delays, and patient compliance for providing second stool specimens can drop as low as 35 percent.

In the United States, commercial labs set independent intermediate ranges. The ARUP Laboratories test directory classifies 49 micrograms per gram or less as normal, 50 to 120 micrograms per gram as borderline elevated with a recommendation to re-evaluate in 4 to 6 weeks, and 121 micrograms per gram or higher as elevated. Its accompanying fact sheet lists normal as 50 or less and borderline as 51 to 120 micrograms per gram.

Specimen Collection Logistics, Sample Stability, and Testing Costs

Accurate calprotectin testing requires an unpreserved stool sample collected in a clean container and refrigerated promptly prior to laboratory analysis.

For standard clinical analysis, ARUP Laboratories test 3002859 requires a 5-gram stool sample in an unpreserved transport vial, with an absolute minimum of 1 gram. Transport in media or chemical preservatives is unacceptable. Stool collection details published through the Diagnostic Laboratory of Oklahoma for Quest Diagnostics (test code 16796) specify 3 grams of solid stool in a sterile, leak-proof container analyzed via chemiluminescence. Quest patient instructions advise using the collection stick to place a walnut-sized stool sample into a clean container, ensuring urine and toilet bowl water do not contaminate the specimen, and returning the sample within 48 hours.

Storage conditions alter measured concentrations over time. While older papers such as Lasson and colleagues (2015) reported calprotectin was stable for up to 3 days at room temperature before experiencing a 28 percent drop by day 7, newer research reveals earlier degradation. Hamer and colleagues (2022) evaluated five commercial immunoassays and found that untreated stool stored at room temperature exhibited statistically significant declines after just one day, with concentrations falling 30 to 60 percent by day 4 across assays. Haisma and colleagues (2020) demonstrated a 35 percent mean decline in raw stool and a 46 percent decline in buffer after 6 days at room temperature, warning that preanalytical degradation leads to false reassurance and undertreatment. Both studies emphasize that prompt refrigeration at 4 degrees Celsius preserves stability. ARUP accepts refrigerated specimens up to 7 days and frozen specimens up to 30 days, while Quest confirms 28 days of frozen stability.

Preanalytical stool handling and consistency also influence extraction recovery. Juricic and colleagues (2019) and Oyaert and colleagues (2014) found that between-method variations depend heavily on stool consistency, with liquid stools prone to under-recovery. Furthermore, Perry and colleagues (BJGP 2024) noted that diagnostic accuracy data in individuals passing formed stools without diarrhea remain lacking. No dietary restrictions or fasting protocols are needed before testing, as verified by direct-to-consumer lab portals like Walk-In Lab.

Laboratory turnaround times typically range from 1 to 4 days at ARUP, 2 to 3 days across NHS pathology networks, 4 to 5 days from receipt at Labcorp OnDemand, and 4 to 7 days via Walk-In Lab. Out-of-pocket cash prices run roughly $135 to $145 at major US consumer storefronts, with Labcorp OnDemand listing the test at $139.00 and Walk-In Lab listing it at $138.00 plus a $6.00 physician order fee (checked September 2026). The standard medical billing code for fecal calprotectin is CPT 83993. Discussing your stool history alongside medication records with your physician is the most reliable way to clarify what a calprotectin test high means for your clinical care.

Related

• How Doctors Test Gut Health: The Clinical Pathways
• Are Gut Health Tests Accurate? Evidence Review
• Best Gut Health Tests Compared
• hsCRP: Systemic Inflammation Testing
• Gut Health Hub: Diagnostics and Biome Tracking
• Leaky gut vs SIBO: where calprotectin sits in the investigation order